Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.67 |
| ▸ | KIF11 | P52732 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29815910 | 0.85 | PARP1 (0.62) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 | |
| SCHEMBL25422100 | 0.81 | PARP1 (0.68) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 | |
| SCHEMBL630161 | 0.80 | CSNK2A1 (0.57) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 | |
| SCHEMBL629270 | 0.80 | PARP1 (1.00) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 | |
| SCHEMBL30704691 | 0.80 | PARP1 (1.00) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 | |
| SCHEMBL2691509 | 0.80 | PARP1 (0.90) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 | |
| SCHEMBL629893 | 0.79 | PARP1 (0.56) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 | |
| SCHEMBL27375411 | 0.78 | KIF11 (0.42) | PARP1CSNK2A1KIF11KDM4E | |
| SCHEMBL4725998 | 0.77 | KIF11 (0.84) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 | |
| SCHEMBL29708168 | 0.77 | KIF11 (0.84) | PARP1CSNK2A1KIF11DYRK1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024052690-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| EP-2061765-B1 | Serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES INC (TW) | 2014-10-22 | — | — | EP | disclosed |
| EP-2061765-B1 | Serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES INC (TW) | 2014-10-22 | — | — | EP | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-2061765-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | PACSIN2, CKS1B, CSNK1A1 | PARP1 1797/4885CSNK2A1 6/4885KIF11 1251/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | PARP1 690/4885CSNK2A1 680/4885KIF11 2815/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | PARP1 3/4885CSNK2A1 24/4885KIF11 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.